Clinical Trials Browser

INDUSTRY × Multiple Myeloma × pembrolizumab × Clear all

Burkitt Lymphoma, Hodgkin Disease, Leukemia, Hairy Cell, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

NCT04354246 2025-05-22

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Phase 1 Active not recruiting

110 enrolled

GastrointestinalGynecologicHead & NeckPlasma cellThoracic

Squamous Cell Carcinoma of Head and Neck, Colonic Neoplasms, Lung Neoplasms, Multiple Myeloma, Ovarian Neoplasms, Neoplasms, Plasma Cell

NCT03848845 2024-04-09

DREAMM 4

Phase 1/2 Completed

41 enrolled 57 charts

Plasma cell

Multiple Myeloma

NCT03168438 2022-01-11

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

Phase 1 Terminated

6 enrolled 19 charts

Plasma cell

Multiple Myeloma, Neoplasms, Recurrence

NCT02576977 2021-10-08

KEYNOTE 183

Phase 3 Terminated

251 enrolled 17 charts

Plasma cell

Multiple Myeloma

NCT01953692 2021-08-04

MK-3475-013

Phase 1 Completed

197 enrolled 52 charts

LymphoidMyeloidPlasma cell

Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Lymphoma, Large B-Cell, Diffuse

NCT02579863 2021-07-20

KEYNOTE 185

Phase 3 Terminated

310 enrolled 16 charts

Plasma cell

Multiple Myeloma

NCT02036502 2021-04-08

MK-3475-023

Phase 1 Terminated

77 enrolled 23 charts

Plasma cell

Multiple Myeloma

NCT03221634 2019-03-25

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)

Phase 2 Withdrawn

Plasma cell

Multiple Myeloma

Clinical Trials

KEYNOTE145

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

DREAMM 4

Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma

KEYNOTE 183

MK-3475-013

KEYNOTE 185

MK-3475-023

Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)